About Oxaloacetate tautomerase FAHD2A, mitochondrial
Oxaloacetate tautomerase FAHD2A, mitochondrial (FAHD2A) is a protein
from Homo sapiens identified by UniProt accession
Q96GK7, 314 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Oxaloacetate tautomerase FAHD2A, mitochondrial |
|---|
| UniProt accession | Q96GK7 |
|---|
| Gene | FAHD2A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 314 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- lysosomal storage disease · score 0.35
- multiple sclerosis · score 0.35
- Parkinson disease · score 0.35
- neurodegenerative disease · score 0.35
- Alzheimer disease · score 0.35
- calcium measurement · score 0.12
- serum urea measurement · score 0.02
- hepatocellular carcinoma · score 0.01
- Obesity · score 0.01
- chronic kidney disease · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96GK7-F1 | alphafold | PREDICTED | 92.75 | — |
Amino-acid sequence (314 residues)
MLVSGRRRLL TVLLQAQKWP FQPSRDMRLV QFRAPHLVGP HLGLETGNGG GVINLNAFDP TLPKTMTQFL EQGEATLSVA RRALAAQLPV LPRSEVTFLA PVTRPDKVVC VGMNYVDHCK EQNVPVPKEP IIFSKFASSI VGPYDEVVLP PQSQEVDWEV ELAVVIGKKG KHIKATDAMA HVAGFTVAHD VSARDWQMRR NGKQWLLGKT FDTFCPLGPA LVTKDSVADP HNLKICCRVN GEVVQSGNTN QMVFKTEDLI AWVSQFVTFY PGDVILTGTP PGVGVFRKPP VFLKKGDEVQ CEIEELGVII NKVV
Explore Oxaloacetate tautomerase FAHD2A, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets